---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005317"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-08-06T20:02:32+00:00"
generated_at: "2026-08-06T20:04:28.467643+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28

## Summary
- Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.
- Cash, equivalents and marketable securities $215.2M at June 30, 2026 (incl. $189.4M from Jan 2026 financing) vs $56.8M at Dec 2025; runway into 2Q28.
- Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track; plans to start hidradenitis suppurativa and asthma trials later 2026.
- Invested $5.0M in Angel Pharma equity financing for soquelitinib trials in China.
- Angel Pharma to initiate Phase 2 asthma trial early 2027; Corvus to start Phase 1b hidradenitis suppurativa and Phase 2 asthma trials later 2026.

## SEC filing metadata
- accession: 0001171843-26-005317
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-08-06T20:02:32+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/0001171843-26-005317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/f8k_080626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005317
- JSON: https://secwatch.observer/filing/0001171843-26-005317.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.